A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)

Exclusion Criteria

• •Has a left ventricular ejection fraction (LVEF) less than (\<) 40 percent (%) based on an echocardiogram (ECHO) performed within 3 months prior to Screening or at the Screening visit
• •Has a QT interval corrected with Fridericia's method (QTcF) \>= 450 millisecond (msec) on the Screening electrocardiogram (ECG)
• •Initiation or change of dosing (except for modifications to accommodate changes in weight) within 12 weeks prior to Screening and while participating in the study for any of the following: angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blocking agents (ARBs), beta-blockers, or potassium
• •Requires antiarrhythmic and/or diuretic therapy for heart failure
• •Forced vital capacity (FVC) \<40% of predicted value within 3 months of Screening or at the Screening visit
• •Known kidney disease or had an acute kidney injury within 6 months prior to Screening
• •Treatment with eteplirsen or drisapersen within 6 months prior to Screening, or any experimental gene therapy for the treatment of DMD at any time
• •Use of any herbal medication/supplement containing aristolochic acid
• •\*The dose of steroids must remain constant except for modifications to accommodate changes in weight.